ID: MRFR/LS/0620-HCR | February 2021 | Region: Global | 200 pages
Blood Transfusion Diagnostics Market Scenario:
Blood Transfusion Diagnostics Market Size is expected to reach USD 2.45 billion in 2023 from USD 1.50 billion in 2016 with a CAGR of approximately 8.2% during the forecast period 2017-2023.
Intravenous transfer of blood or blood products is known as blood transfusion. Replacement of lost blood components can be done with the help of blood transfusion. Blood components like red blood cells, white blood cells, platelets, clotting factors and plasma are mostly transfused. These blood components are of great importance to laboratories and hospitals during an emergency or a critical case of large volume of blood loss. RBC transfusion is done when hemoglobin levels fall below 100g/L. Blood collected from the donor has to be screened for a number of infectious disease before transfusion. Thus, blood transfusion diagnostics play an important role in blood transfusion in order to avoid infection to both the receiver and healthcare staff. Rising prevalence of infectious diseases, increasing in number of blood transfusion procedures, demand for screened blood products and increasing campaigning or awareness programs drive the growth of this market. Demand of blood and blood products exceeds over their supply thus contributing to the growth of this market.
Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.
Figure 1: Blood Transfusion Diagnostics market, by technology, 2016:
Source: Press Release, Company presentation, annual reports
Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products. On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.
Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.
Figure 2: Market Synopsis
Sources: Press Release, presentation, company website, annual reports, government records, journals expert interview.
Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Immucor (U.S), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics (U.S), Beckman Coulter (U.S), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).
The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Frequently Asked Questions (FAQ) :
Global Blood Transfusion Diagnostics Market is expected to be valued at USD 2.45 billion in 2023, rising from USD 1.5 billion in 2016.
Blood Transfusion Diagnostics Market is expected to exhibit a strong 8.2% CAGR over the forecast period from 2017 to 2023.
Increasing volume of blood transfusions is likely to be a key driver for the Blood Transfusion Diagnostics Market.
Americas are the largest Blood Transfusion Diagnostics Market.
Leading players in the Blood Transfusion Diagnostics Market include Roche Diagnostics, Thermo Fisher, and Grifols, among others.